SELLAS Life Sciences Group, Inc. (SLS) Financials

SLS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 114.2 million 6.8 million
Dec. 31, 2025 78.3 million 7.5 million
Sept. 30, 2025 51.6 million 5.9 million
June 30, 2025 32.3 million 6.2 million

SLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -8.8 million 798000
Dec. 31, 2025 -4.9 million 447000
Sept. 30, 2025 -7.1 million 503000
June 30, 2025 -7.3 million 501000

SLS Net Income

No data available :(

SLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 107.2 million 309000 871000
Dec. 31, 2025 71.9 million 457000 1.0 million
Sept. 30, 2025 44.4 million - 599000
June 30, 2025 25.3 million - 737000

SLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 172.5 million
Dec. 31, 2025 153.1 million
Sept. 30, 2025 108.4 million
June 30, 2025 98.6 million

SLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 5.1 million 4.1 million -
Dec. 31, 2025 - 4.7 million 3.5 million -
Sept. 30, 2025 - 4.2 million 2.9 million -
June 30, 2025 - 3.9 million 3.0 million -

SLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -
June 30, 2025 - -

SLS

Price: $7.73

52 week price:
1.39
9.51

Earnings Per Share: -0.23 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 183300

Ebitda: -4.4 million

Market Capitalization: 1.2 billion

Links: